Title:
COMPOSITIONS AND METHODS OF COMBINATION THERAPY FOR TARGETING LYMPHOMA
Document Type and Number:
WIPO Patent Application WO/2023/011533
Kind Code:
A1
Abstract:
Provided are compositions, their combinations, and their uses thereof, for example in treating a cancer, such as a lymphoma. Some embodiments include providing an Enhancer of Zeste Homolog 2 (EZH2) inhibitor and an immunomodulatory drug to a subject having the cancer.
Inventors:
WANG JIALIANG (US)
LIU JING (US)
ZHANG CHENGWEI (CN)
YANG TING (CN)
LIU JING (US)
ZHANG CHENGWEI (CN)
YANG TING (CN)
Application Number:
PCT/CN2022/109992
Publication Date:
February 09, 2023
Filing Date:
August 03, 2022
Export Citation:
Assignee:
CULLGEN SHANGHAI INC (CN)
International Classes:
A61K31/444; A61K31/5377; A61P35/00
Domestic Patent References:
| WO2018099803A1 | 2018-06-07 | |||
| WO2019050924A1 | 2019-03-14 |
Other References:
DREW，A.E. ET AL.: "Abstract 807: Mechanism of action of synergistic activity of EZH2 inhibition and IMiDs in preclinical multiple myeloma models.", CANCER RESEARCH, AMERICAN ASSOCIATION FOR CANCER RESEARCH, US, vol. 78, no. 13-Supplement, 31 December 2018 (2018-12-31), US, pages 807 - 807, XP009543241, ISSN: 0008-5472, DOI: 10.1158/1538-7445.AM2018-807
LAURIE HERVIOU: "Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs", 6 December 2016 (2016-12-06), XP055360000, Retrieved from the Internet [retrieved on 20170329]
KONSTANTINOS DIMOPOULOS, ALEXANDRA SØGAARD HELBO, HELGA FIBIGER MUNCH-PETERSEN, LENE SJÖ, JESPER CHRISTENSEN, LASSE SOMMER KRISTEN: "Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a Cereblon-independent manner", MOLECULAR ONCOLOGY, ELSEVIER, XP055429678, ISSN: 1574-7891, DOI: 10.1002/1878-0261.12157
RICHART，L. ET AL.: "Drugging histone methyltransferases in cancer.", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 56, 31 December 2020 (2020-12-31), pages 51 - 62, XP086198657, DOI: 10.1016/j.cbpa.2019.11.009
MULLARD，A.: "Targeted protein degraders crowd into the clinic.", NATURE REVIEWS DRUG DISCOVERY, vol. 20, 30 April 2021 (2021-04-30), pages 247 - 250, XP037417632, DOI: 10.1038/d41573-021-00052-4
WANG，S. ET AL.: "Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.", BIOMARKER RESEARCH, vol. 9, 5 June 2021 (2021-06-05), XP021292009, DOI: 10.1186/s40364-021-00297-6
LAURIE HERVIOU: "Targeting EZH2 in Multiple Myeloma Could be Promising for a Subgroup of MM Patients in Combination with IMiDs", 6 December 2016 (2016-12-06), XP055360000, Retrieved from the Internet
KONSTANTINOS DIMOPOULOS, ALEXANDRA SØGAARD HELBO, HELGA FIBIGER MUNCH-PETERSEN, LENE SJÖ, JESPER CHRISTENSEN, LASSE SOMMER KRISTEN: "Dual inhibition of DNMTs and EZH2 can overcome both intrinsic and acquired resistance of myeloma cells to IMiDs in a Cereblon-independent manner", MOLECULAR ONCOLOGY, ELSEVIER, XP055429678, ISSN: 1574-7891, DOI: 10.1002/1878-0261.12157
RICHART，L. ET AL.: "Drugging histone methyltransferases in cancer.", CURRENT OPINION IN CHEMICAL BIOLOGY, vol. 56, 31 December 2020 (2020-12-31), pages 51 - 62, XP086198657, DOI: 10.1016/j.cbpa.2019.11.009
MULLARD，A.: "Targeted protein degraders crowd into the clinic.", NATURE REVIEWS DRUG DISCOVERY, vol. 20, 30 April 2021 (2021-04-30), pages 247 - 250, XP037417632, DOI: 10.1038/d41573-021-00052-4
WANG，S. ET AL.: "Key regulators of sensitivity to immunomodulatory drugs in cancer treatment.", BIOMARKER RESEARCH, vol. 9, 5 June 2021 (2021-06-05), XP021292009, DOI: 10.1186/s40364-021-00297-6
Attorney, Agent or Firm:
AFD CHINA INTELLECTUAL PROPERTY LAW OFFICE (CN)
Download PDF: